Anti-C1T9A/ C1QTNF9/ AQL1A functional antibody
Anti-C1T9A/ C1QTNF9/ AQL1A functional antibody for cell culture, ELISA & in-vivo assay
Go to C1QTNF9/C1QTNF9 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0717-Ab-1/ GM-Tg-hg-SE0717-Ab-2 | Anti-Human C1QTNF9 monoclonal antibody | Human |
GM-Tg-rg-SE0717-Ab-1/ GM-Tg-rg-SE0717-Ab-2 | Anti-Rat C1QTNF9 monoclonal antibody | Rat |
GM-Tg-mg-SE0717-Ab-1/ GM-Tg-mg-SE0717-Ab-2 | Anti-Mouse C1QTNF9 monoclonal antibody | Mouse |
GM-Tg-cynog-SE0717-Ab-1/ GM-Tg-cynog-SE0717-Ab-2 | Anti-Cynomolgus/ Rhesus macaque C1QTNF9 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0717-Ab-1/ GM-Tg-felg-SE0717-Ab-2 | Anti-Feline C1QTNF9 monoclonal antibody | Feline |
GM-Tg-cang-SE0717-Ab-1/ GM-Tg-cang-SE0717-Ab-2 | Anti-Canine C1QTNF9 monoclonal antibody | Canine |
GM-Tg-bovg-SE0717-Ab-1/ GM-Tg-bovg-SE0717-Ab-2 | Anti-Bovine C1QTNF9 monoclonal antibody | Bovine |
GM-Tg-equg-SE0717-Ab-1/ GM-Tg-equg-SE0717-Ab-2 | Anti-Equine C1QTNF9 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0717-Ab-1/ GM-Tg-hg-SE0717-Ab-2; GM-Tg-rg-SE0717-Ab-1/ GM-Tg-rg-SE0717-Ab-2; GM-Tg-mg-SE0717-Ab-1/ GM-Tg-mg-SE0717-Ab-2; GM-Tg-cynog-SE0717-Ab-1/ GM-Tg-cynog-SE0717-Ab-2; GM-Tg-felg-SE0717-Ab-1/ GM-Tg-felg-SE0717-Ab-2; GM-Tg-cang-SE0717-Ab-1/ GM-Tg-cang-SE0717-Ab-2; GM-Tg-bovg-SE0717-Ab-1/ GM-Tg-bovg-SE0717-Ab-2; GM-Tg-equg-SE0717-Ab-1/ GM-Tg-equg-SE0717-Ab-2 |
Products Name | Anti-C1QTNF9 monoclonal antibody |
Format | mab |
Target Name | C1QTNF9 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-C1QTNF9 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0717-Ag-1 | Recombinant multi-species C1T9A/ C1QTNF9/ AQL1A protein |
ORF Viral Vector | pGMAAV000110 | mouse C1qtnf9 AAV plasmid |
ORF Viral Vector | vGMAAV000110 | mouse C1qtnf9 AAV particle |
Target information
Target ID | GM-SE0717 |
Target Name | C1QTNF9 |
Gene ID | 338872,523616,100050508 |
Gene Symbol and Synonyms | AQL1,C1QTNF9,C1QTNF9A,CTRP9 |
Uniprot Accession | P0C862,Q0II24 |
Uniprot Entry Name | C1T9A_HUMAN,C1QT9_BOVIN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000240654 |
Target Classification | N/A |
The target: C1QTNF9, gene name: C1QTNF9, also named as AQL1A, CTRP9, C1QTNF9. Enables identical protein binding activity. Predicted to be involved in signal transduction. Predicted to be located in extracellular region. Predicted to be part of collagen trimer. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.